Nanoscope Therapeutics Inc.

Nanoscope Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing gene therapies for retinal degenerative diseases. Headquartered in Dallas, Texas, the company's core mission is to restore vision, enhance quality of life, and instill renewed hope for individuals affected by various forms of retinal degeneration, aiming to provide solutions where no cure currently exists.

The company's primary product is MCO-010 (also known as MOGENRY™), a proprietary ambient light-activated optogenetic gene therapy. This innovative treatment utilizes Multi-Characteristic Opsin (MCO) to re-sensitize retinal cells, enabling vision restoration in patients suffering from conditions such as Retinitis Pigmentosa (RP), Stargardt disease, and dry age-related macular degeneration (geographic atrophy). MCO-010 is designed as a gene-agnostic, one-time, in-office intravitreal injection, eliminating the need for genetic testing, invasive surgery, or repeat dosing, thereby offering broad applicability for patients with severe vision loss.

Nanoscope Therapeutics is actively advancing its therapies through clinical development. The company initiated a rolling Biologics License Application (BLA) submission to the FDA for MCO-010 for retinitis pigmentosa in June 2025, with full submission expected in early 2026. MCO-010 has received Fast Track and Orphan Drug designations from the U.S. FDA for RP and Stargardt disease, and an Orphan Drug Designation in Saudi Arabia. Recent positive 3-year follow-up data from the REMAIN study demonstrated durable and clinically meaningful vision improvements in RP patients. The company is also planning a Phase 3 clinical trial for MCO-010 in advanced Stargardt disease, with patient dosing anticipated in Q1 2025. Leadership includes Co-Founder and CEO Sulagna Bhattacharya, with Paul Hallen appointed Chief Operating Officer in April 2026 to spearhead global commercial readiness.